Cancer Vaccines Market, by Technology (Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, and Viral Vector & DNA Cancer Vaccines), Type (Preventive Cancer Vaccines and Therapeutic Cancer Vaccines), Indication (Cervical Cancer, Prostate Cancer, and Others), and End User (Pediatrics and Adults): Global Opportunity Analysis and Industry Forecast, 2020-2027

Cancer Vaccines Market Statistics, 2027

The global cancer vaccines market was valued at $4,188 million in 2019, and is projected to reach $7,303 million by 2027, registering a CAGR of 12.6% from 2020 to 2027. Cancer vaccines are medicines considered as biological response modifiers. These biological response modifiers work by stimulating the immune system of body to fight against cancer. Preventive cancer vaccines and therapeutic cancer vaccines are two types of cancer vaccines. Preventive cancer vaccines are used in healthy person to prevent cancer. Therapeutic cancer vaccines are used in cancer patients to strengthen their immune response to fight against the disease. Cancer vaccines can be administered intravenously (IV) in children as well as in adults.

Increase in number of cancer patients, rise in geriatric population, surge in patient awareness towards cancer therapy, increase in cancer vaccines usage combined with other therapies, increase in prevalence of human papilloma virus (HPV) infections, and increase in investments and government funding in development of cancer vaccines by manufacturers are the major factors that drive growth of the cancer vaccines market. In addition, technological developments in cancer vaccines, launch of novel cancer vaccines, rise in health care services and expenditure, and rise in adoption rates of preventive and therapeutic vaccines are some other factors that contribute toward growth of the market. Moreover, increase in tobacco consumption and unhealthy dietary habits are leading risk factors for the rise in number of cancer cases, which further drives growth of the cancer vaccines market. However, high cost for developing cancer vaccines and longer time span required for manufacturing a single vaccine are anticipated to restrict the market growth.

COVID-19 Impact on Cancer Vaccines Market

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Cancer vaccines manufacturing and distributing companies have been affected by COVID-19 to a limited extent, owing to shutdown in various COVID-19 affected countries and rise in number of healthcare workers falling ill in the wake of the COVID-19 pandemic, leading to short supply.

Cancer Vaccines Market Segmentation

The global cancer vaccines market is segmented on the basis of technology, type, indication, end user, and region. By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines. By type, it is bifurcated into preventive cancer vaccines and therapeutic cancer vaccines. By indication, it is classified into cervical cancer, prostate cancer, and others. By end user, it is divided into pediatric and adult. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

By Technology

Presently, on the basis of technology, the recombinant cancer vaccines segment is the major revenue contributor, and is projected to grow significantly during the forecast period. Increase in adoption of recombinant technology, rise in utilization of recombinant vaccines, and surge in number of approved cancer vaccines developed using recombinant technology are the key factors that boost growth of the segment.

By Indication

Depending on indication, the cervical cancer segment is the major shareholder in the global cancer vaccines market, owing to high prevalence of cervical cancer and increase in number of people suffering from human papilloma virus (HPV) infections. In addition, rise in geriatric population, drug development in the field of cervical cancer, and increase in patient awareness toward cervical cancer drive growth of the segment.

Snapshot of Asia-Pacific Cancer Vaccines Market

Asia-Pacific presents lucrative opportunities for key players operating in the cancer vaccines market, owing to rise in adoption of cancer vaccines, increase in number of cancer patients in emerging economies, development of the R&D sector, rise in healthcare reforms, and technological advancements in cancer vaccines. Moreover, rise in demand for cancer vaccines, surge in funding from government and non-government sectors to develop novel cancer vaccines, rise in number of hospitals & diagnostic centers equipped with advanced medical facilities, and presence of high population base contributes toward growth of the market. Moreover, surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high market share is expected to drive growth of the cancer vaccines market in the region.

Competitive Analysis

The key players profiled in this report include Advaxis Inc., Amgen Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, GlaxoSmithKline plc (GSK), Immunocellular Therapeutics, Ltd, Merck & Co., Inc., Sanpower Group Co. Ltd. (Dendereon Corporation), UbiVac, and Vaccinogen, Inc.

Key Benefits for Stakeholders:

• The study provides an in-depth analysis of the cancer vaccines market size along with the current trends and future estimations to elucidate imminent investment pockets.
• It offers cancer vaccines market analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on prevailing opportunities in the market.
• A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global cancer vaccines market growth.

Key Market Segments:

By Technology 

• Dendritic Cells (DC) Cancer Vaccines
• Recombinant Cancer Vaccines
• Antigen/Adjuvant Cancer Vaccines
• Viral Vector & DNA Cancer Vaccines

By Indication

• Cervical Cancer
• Prostate Cancer
• Others 

By Type

• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines 

By End User

• Pediatrics 
• Adults 

By Region

• North America

  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China 
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Argentina
  • Turkey
  • South Africa
  • Rest of LAMEA

  Cancer Vaccines Market, by Technology Report Highlights

Aspects	Details
By TECHNOLOGY	Dendritic Cells (DC) Cancer Vaccines Recombinant Cancer Vaccines Antigen/Adjuvent Cancer Vaccines Viral Vector and DNA Cancer Vaccines
By TYPES	Preventive Cancer Vaccines Therapeutic Cancer Vaccines
By INDICATION	Cervical Cancer Prostate Cancer Other Indications
By END USER	Pediatrics Adults
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Dynavax Technologies Corporation, Merck & Co., Inc., Immunocellular Therapeutics, Ltd, UbiVac, Advaxis Inc., Vaccinogen, Inc., GlaxoSmithKline plc (GSK), SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION), Generex Biotechnology Corporation, Amgen Inc.

Analyst Review

Cancer vaccines are medications that stimulate the immune system of the body to fight against disease. Moreover, it can be administered intravenously in children as well as adults. 

Rise in prevalence of cancer, increase in demand for novel cancer vaccine products, rise in adoption rates of preventive and therapeutic vaccines, and rise in investments by government & private organizations for the production of cancer vaccines significantly boost growth of the cancer vaccines market. However, high cost for developing cancer vaccines and longer time required for manufacturing a single vaccine are anticipated to restrict the market growth.

North America is expected to remain dominant during the forecast period, owing to rise in cases of cancer, high unmet demand for cancer vaccines, higher healthcare awareness, presence of well-developed healthcare infrastructure, presence of trained medical professionals, and early detection of the disease, which supports the market growth. In addition, strong reimbursement policies, presence of large number of hospitals & diagnostic centers equipped with advanced healthcare systems, and strong presence of key players supplement growth of the market in the region. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to key players during the forecast period, owing to rise in number of cancer affected population with rise in demand for cancer vaccines.

 

 

 

 

 

 

 

 

 

Author Name(s) : Sanjivan Gill| Sushant Terdale | Roshan Deshmukh

Related Tags

• Chemotherapy
• Cancer Drugs
• Cancer Diagnostics
• Cancer Therapy

^*Terms and Conditions Apply